Candidiasis, also known as thrush, is a fungal infection caused by any type of Candida, which are yeasts that naturally inhabit the skin and mucous membranes. Candida infections can cause oral thrush, vaginal thrush, respiratory infections and invasive candidiasis. Candidiasis is commonly treated with antifungal medications such as fluconazole and itraconazole. Increasing cases of drug resistant candida strains is stimulating the demand for combination therapy. Combination treatment involves the use of two or more antifungal drugs that act on different biochemical targets to increase efficacy and prevent or delay resistance. The growing adoption of combination therapies for treatment of severe and recurrent candidiasis is expected to drive the growth of the global candidiasis market over the forecast period.
The global Candidiasis Market is estimated to be valued at US$ 984.8 Mn in 2023 and is expected to exhibit a CAGR of 8.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The growing adoption of combination therapies is one of the key drivers propelling the growth of the candidiasis market. Combination therapy helps overcome antifungal resistance and achieves faster mycological cure and clinical response compared to monotherapy. This is encouraging pharmaceutical companies to invest in development of novel antifungal drug combinations. For instance, in April 2019, SCYNEXIS, Inc. announced positive top-line results from its phase 3 VANISH study, which evaluated oral ibrexafungerp in combination with other anti-fungals for the treatment of vulvovaginal candidiasis.
The rising prevalence of opportunistic fungal infections including candidiasis among immunocompromised patients also contributes to the market growth. Moreover, candidiasis caused by non-albicans Candida strains, which are less susceptible to azole drugs, is elevating the need for more effective treatment options. This is stimulating research activities directed towards development of therapies against emerging multidrug-resistant Candida species.
Segment Analysis
The global candidiasis market size is segmented on the basis of disease type, treatment type, and end user. Based on disease type, the market has been segmented into vulvovaginal candidiasis, oral thrush, esophageal candidiasis, and others. The vulvovaginal candidiasis segment currently dominates the market due to its high frequency rate. Social: In terms of treatment type, the market is categorized into antifungals, antibiotics, and others. The antifungals segment holds the largest share as it is the most prescribed and effective treatment for candidiasis. Hospitals accounted for the largest share in the end user segment owing to high patient pool and availability of advanced treatment facilities.
PEST Analysis
Political: Government initiatives to spread awareness regarding fungal diseases among populace. Several funding schemes to encourage research on novel anti-fungal drugs.
Economic: Rising healthcare expenditure in developing nations expected to drive market growth. Increased affordability of anti-fungal drugs to positively impact the candidiasis market size.
Social: Widening patient pool suffering from Candida infections globally due to sedentary lifestyle and weak immunity. Higher risk among HIV/AIDS patients may support market expansion.
Technological: Advancements in diagnostic techniques allow for early detection. Novel drug delivery systems and combination therapies being researched.
Key Takeaways
The global candidiasis market size was valued at US$ 984.8 million in 2024 and is expected to expand at a CAGR of 8.8% during the forecast period. Vulvovaginal candidiasis segment holds the largest share currently due to its high frequency of occurrence. The global Candidiasis Market is estimated to be valued at US$ 984.8 Mn in 2023 and is expected to exhibit a CAGR of 8.8% over the forecast period 2023 to 2030.
Regionally, North America dominates the candidiasis market due to growing prevalence of yeast infections and technological advancements.
Key players operating in the candidiasis market are Basilea Pharmaceutica Ltd, Astellas Pharma Inc., SCYNEXIS, Inc., NovaDigm Therapeutics, Mycovia Pharmaceuticals, Inc., Pfizer Inc, and Viatris Inc. Basilea Pharmaceuticals holds a significant share due to its strong product portfolio and global presence.
